Circulating microRNAs Signature for Predicting Response to GLP1-RA Therapy in Type 2 Diabetic Patients: A Pilot Study

Circulating microRNAs Signature for Predicting Response to GLP1-RA Therapy in Type 2 Diabetic Patients: A Pilot Study

Type 2 diabetes (T2D) represents one of the major health issues of this century. Despite the availability of an increasing number of anti-hyperglycemic drugs, a significant proportion of patients are inadequately controlled, thus highlighting the need for novel biomarkers to guide treatment selectio...

Full description

Bibliographic Details
Main Authors:	Caterina Formichi, Daniela Fignani, Laura Nigi, Giuseppina Emanuela Grieco, Noemi Brusco, Giada Licata, Claudia Sabato, Elisabetta Ferretti, Guido Sebastiani, Francesco Dotta
Format:	Article
Language:	English
Published:	MDPI AG 2021-08-01
Series:	International Journal of Molecular Sciences
Subjects:	microRNAs GLP1-RA type 2 diabetes obesity personalized medicine
Online Access:	https://www.mdpi.com/1422-0067/22/17/9454

Similar Items

The Landscape of microRNAs in βCell: Between Phenotype Maintenance and Protection
by: Giuseppina Emanuela Grieco, et al.
Published: (2021-01-01)

Non-Coding RNAs: Novel Players in Insulin Resistance and Related Diseases
by: Caterina Formichi, et al.
Published: (2021-07-01)

Reduced miR-184-3p expression protects pancreatic β-cells from lipotoxic and proinflammatory apoptosis in type 2 diabetes via CRTC1 upregulation
by: Giuseppina E. Grieco, et al.
Published: (2022-07-01)

Circulating microRNA (miRNA) Expression Profiling in Plasma of Patients with Gestational Diabetes Mellitus Reveals Upregulation of miRNA miR-330-3p
by: Guido Sebastiani, et al.
Published: (2017-12-01)

The Role of GLP1-RAs in Direct Modulation of Lipid Metabolism in Hepatic Tissue as Determined Using In Vitro Models of NAFLD
by: Ana Petrovic, et al.
Published: (2023-05-01)

GLP-1RA may have varying effects on cardiac structure in patients with ASCVD depending on BMI
by: Ling Xu, et al.
Published: (2024-03-01)

SARS-CoV-2 Receptor Angiotensin I-Converting Enzyme Type 2 (ACE2) Is Expressed in Human Pancreatic β-Cells and in the Human Pancreas Microvasculature
by: Daniela Fignani, et al.
Published: (2020-11-01)

Underlying mechanisms and cardioprotective effects of SGLT2i and GLP-1Ra: insights from cardiovascular magnetic resonance
by: Angelica Cersosimo, et al.
Published: (2024-03-01)

GLP-1RA Essentials in Gastroenterology: Side Effect Management, Precautions for Endoscopy and Applications for Gastrointestinal Disease Treatment
by: Justin Wan, et al.
Published: (2024-02-01)

Efficacy of GLP-1rA, liraglutide, in plaque psoriasis treatment with type 2 diabetes: a systematic review and meta-analysis of prospective cohort and before-after studies
by: Guizhen Chang, et al.
Published: (2022-04-01)

GLP-1 receptor agonist-associated tumor adverse events: A real-world study from 2004 to 2021 based on FAERS
by: Zheng Yang, et al.
Published: (2022-10-01)

Heterogeneity amongst GLP-1 RA cardiovascular outcome trials results: can definition of established cardiovascular disease be the missing link?
by: Miguel Melo, et al.
Published: (2021-07-01)

Expert Opinion on Diabetes Management Challenges and Role of Basal Insulin/GLP-1 RA Fixed-Ratio Combination in People with Type 2 Diabetes from Indonesia
by: Suastika K, et al.
Published: (2022-09-01)

Clinical Effectiveness and Safety of Once-Weekly GLP-1 Receptor Agonist Dulaglutide as Add-On to Metformin or Metformin Plus Insulin Secretagogues in Obesity and Type 2 Diabetes
by: Maria Mirabelli, et al.
Published: (2021-03-01)

Efficacy of Glucagon-Like Peptide-1 Analogs in Nonalcoholic Fatty Liver Disease: A Systematic Review
by: Teshome G, et al.
Published: (2020-09-01)

Postmarket safety profile of suicide/self-injury for GLP-1 receptor agonist: a real-world pharmacovigilance analysis
by: Congqin Chen, et al.
Published: (2023-01-01)

Call to action: Understanding the differences in the use of SGLT-2 inhibitors and GLP-1 receptor agonists
by: Apurva Khedagi, et al.
Published: (2023-03-01)

Advances in GLP-1 treatment: focus on oral semaglutide
by: Freddy G. Eliaschewitz, et al.
Published: (2021-09-01)

GLP-1 receptor agonist as an effective treatment for breast cancer-related lymphedema: a case report
by: Fionnuala Crowley, et al.
Published: (2024-04-01)

Pancreatic Alpha-Cells Contribute Together With Beta-Cells to CXCL10 Expression in Type 1 Diabetes
by: Laura Nigi, et al.
Published: (2020-09-01)

MicroRNAs (miRNAs) in Cardiovascular Complications of Rheumatoid Arthritis (RA): What Is New?
by: Daniela Maria Tanase, et al.
Published: (2022-05-01)

Basal insulin intensification with GLP-1RA and dual GIP and GLP-1RA in patients with uncontrolled type 2 diabetes mellitus: A rapid review of randomized controlled trials and meta-analysis
by: Giuseppe Lisco, et al.
Published: (2022-09-01)

Free Versus Fixed-Ratio Combination of Basal Insulin and GLP-1 Receptor Agonists in Type 2 Diabetes Uncontrolled With GLP-1 Receptor Agonists: A Systematic Review and Indirect Treatment Comparison
by: Han Na Jung, et al.
Published: (2022-05-01)

[Gly²]-GLP-2, But Not Glucagon or [D-Ala²]-GLP-1, Controls Collagen Crosslinking in Murine Osteoblast Cultures
by: Aleksandra Mieczkowska, et al.
Published: (2021-08-01)

Anti-Inflammatory Effects of GLP-1 Receptor Activation in the Brain in Neurodegenerative Diseases
by: Yolanda Diz-Chaves, et al.
Published: (2022-08-01)

Anti-Inflammatory Effects of GLP-1R Activation in the Retina
by: Alessandra Puddu, et al.
Published: (2022-10-01)

Risk of stroke and retinopathy during GLP-1 receptor agonist cardiovascular outcome trials: An eight RCTs meta-analysis
by: Jinjing Wei, et al.
Published: (2022-12-01)

The Impact of GLP1 Agonists on Bone Metabolism: A Systematic Review
by: Ioanna Daniilopoulou, et al.
Published: (2022-02-01)

GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs
by: Dario Giugliano, et al.
Published: (2021-09-01)

Long-acting agonists of human and rodent GLP-2 receptors for studies of the physiology and pharmacological potential of the GLP-2 system
by: Sarina Gadgaard, et al.
Published: (2023-04-01)

Effects of GLP-1 receptor agonists on mitochondrial function, inflammatory markers and leukocyte-endothelium interactions in type 2 diabetes
by: Clara Luna-Marco, et al.
Published: (2023-10-01)

Evidence for Cardiorenal Protection with SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Patients with Diabetic Kidney Disease
by: Panagiotis I. Georgianos, et al.
Published: (2022-02-01)

GLP-1 vasodilatation in humans with coronary artery disease is not adenosine mediated
by: Muhammad Aetesam-ur-Rahman, et al.
Published: (2021-05-01)

TXNIP reduces pro-proliferation effect of GLP-1 on mouse islet β cells
by: ZHANG Wen-ting, WANG Jin, YUE Ji-ping, JIN Wen-wen, ZHANG Zhi-nan, JIAO Xiang-ying
Published: (2020-08-01)

Rate of Homologous Desensitization and Internalization of the GLP-1 Receptor
by: Ghina Shaaban, et al.
Published: (2016-12-01)

Analogos de GLP1: marcando nuevas rutas en el manejo de la diabetes
by: Luz Angela Casas Figueroa
Published: (2022-06-01)

The relationship between the use of GLP-1 receptor agonists and the incidence of respiratory illness: a meta-analysis of randomized controlled trials
by: Meixin Yu, et al.
Published: (2023-07-01)

Berberine enhances the function of db/db mice islet β cell through GLP-1/GLP-1R/PKA signaling pathway in intestinal L cell and islet α cell
by: Wenbin Wu, et al.
Published: (2023-07-01)

Glucometabolic outcomes of GLP-1 receptor agonist-based therapies in patients with type 2 diabetes: a systematic review and network meta-analysisResearch in context
by: Irene Caruso, et al.
Published: (2023-10-01)

GLP-1 analogs in the treatment of obesity
by: Aleksandra Metelska, et al.
Published: (2022-08-01)